22亿美元!诺和诺德再次合作开发口服小分子减肥药

Medaverse
15 May

5月14日,加利福尼亚州南旧金山,Septerna(NASDAQ:SEPN)和诺和诺德宣布了一项独家全球合作和许可协议,以发现、开发和商业化治疗肥胖、2型糖尿病和其他心脏代谢疾病的口服小分子药物。该交易预计2025年Q2季度完成。这些合作最初将启动四个针对一个或多个选定的G蛋白偶联受体(GPCR)靶点的潜在小分子新药开发项目,包括GLP-1、GIP和胰高血糖素受体。诺和诺德执行副总裁兼首席科学官...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10